TAK: 6-K company filing

6-K 1 form6k_073026.htm 6-K Document FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Commission File Number: 001-38757 For the month of July 2026 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐ Information furnished on this form: EXHIBIT Exhibit Number 1. (English Translation) Earnings Report (Kessan Tanshin) for the Three-month Period Ended June 30, 2026 99.1 Financial Appendix SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TAKEDA PHARMACEUTICAL COMPANY LIMITED Date: July 30, 2026 By: /s/ Norimasa Takeda Norimasa Takeda Chief Accounting Officer and Corporate Controller Earnings Report ( Kessan Tanshin ) for the Three-month Period Ended June 30, 2026 (IFRS, Consolidated) July 30, 2026 Takeda Pharmaceutical Company Limited Stock exchange listings: Tokyo, Nagoya, Sapporo, Fukuoka TSE Code: 4502 URL: https://www.takeda.com Representative: Julie Kim, President & CEO Contact: Christopher O'Reilly Telephone: +81-3-3278-2111 Email: takeda.ir.contact@takeda.com Global Head of IR, G